Pseudomyogenic hemangioendothelioma: t(7;19)(q22;q13) SERPINE1/FOSB by Walther, Charles & Mertens, Fredrik
Solid Tumour Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(10) 630 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
Pseudomyogenic hemangioendothelioma: 
t(7;19)(q22;q13) SERPINE1/FOSB 
Charles Walther, Fredrik Mertens 
Department of Pathology, University, Regional Laboratories, Skne University Hospital, 221 85 Lund, 
Charles.walther@med.lu.se (CW; Department of Clinical Genetics, University, Regional Laboratories, 
Skne University Hospital, Lund University, 221 85 Lund, Fredrik.Mertens@med.lu.se (FM) Sweden 
Published in Atlas Database: December 2014 
Online updated version : http://AtlasGeneticsOncology.org/Tumors/PHEt0719q22q13ID6473.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62484/12-2014-PHEt0719q22q13ID6473.pdf 
DOI: 10.4267/2042/62484
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
Pseudomyogenic hemangioendothelioma (PHE) is 
an intermediate malignant vascular tumor primarily 
affecting soft tissues in children and young adults. 
The molecular basis of this neoplasm is unknown. 
Chromosome banding analysis, fluorescence in situ 
hybridization (FISH), mRNA sequencing, RT-PCR, 
and quantitative real-time PCR have shown that 
PHEs are characterized by a balanced translocation 
t(7;19)(q22;q13), resulting in the fusion of the 
SERPINE1 and FOSB genes. The role of 
SERPINE1, which is highly expressed in vascular 
cells, in this gene fusion is probably to provide a 
strong promoter for FOSB. FOSB encodes a 
transcription factor belonging to the FOS family of 
proteins, which together with members of the JUN 
family of transcription factors are major 




SERPINE1; FOSB; translocation 
Clinics and pathology 
Note 





Often young adults. Predominantly male (4.6:1) 
Clinics 
Two thirds of the lesions seen in limbs followed by 
trunk and head and neck. Size 0.3-5.5 cm. Often 
multifocal and ill circumscribed. Situated 
subcutanously but often in different tissue planes, 
including bone. Painful nodules in 50% of the 
cases. Locally aggressive and often recurring but 
rarely distant metastases. (Hornick et al., 2011) 
Pathology 
Spindle cells in fascicles and sheets. Vesicular 
nuclei. Distinct eosinophilic cytoplasm. Cells often 




PHE consistently displays a SERPINE1-FOSB 
fusion gene, resulting from a translocation between 
chromosomes 7 and 19, presumably constituting the 
essential driver mutation in this neoplasm 
(Trombetta et al., 2011). 
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Chromatogram showing the fusion junction in a case of PHE. Sixty-one nucleotides from intron 1 of SERPINE1 were inserted at 





a recurrent translocation t(7;19)(q22;q13) has been 
seen. 
Genes involved and 
proteins 
Note 




DNA / RNA 
12,178 nt 
Protein 
SERPINE1 (aka PAI-1, plasminogen activator 
inhibitor type 1) encodes a protein that is a member 
of the serine protease inhibitor family, and that 
inhibits tissue- and urokinase-type plasminogen 
activators. These activators convert plasminogen to 
plasmin, which in turn mediates fibrinolysis and 
proteolytic degradation of extracellular matrix. It is 
highly expressed in many tumors, being implicated 
in invasion, angiogenesis and metastasis (Declerck 




DNA / RNA 
7,185 nt 
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Protein 
Member of FOS family of genes, which code for 
leucine zipper proteins that act as transcription 
factors. FOSB consists of 338 amino acids (aa), 
with a central basic leucine-zipper region and a 
carboxy-terminal transactivation domain (TAD) 
(Milde-Langosh, 2005). 




RT-PCR and subsequent sequencing of amplified 
products from two cases identified an in-frame 
SERPINE-/FOSB fusion transcripts in both cases. 
In both tumors the breakpoints in SERPINE1 were 
located in the non-coding exon 1. The breakpoint in 
FOSB was located in the beginning of exon 2 in 
one case and in the non-coding exon 1 in the other. 
Both cases showed small insertions (61 bp in Case 
1, 59 bp in Case 2) of material from intron 1 of 




The role of SERPINE1 in the SERPINE1-FOSB  
chimera is probably to provide a promoter allowing 
strong expression of FOSB. 
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